Health knowledge made personal
Join this community!
› Share page:
Search posts:

Farmed Fish May Pose Risk For Mad Cow Disease

Posted Jun 29 2009 5:17pm
The number of articles about the safety of eating farmed fish and mad cow disease (Creutzfeldt Jakob disease) are growing fast on the Internet.

This was triggered by a recent study published in the Journal of Alzheimer’s Disease by University of Louisville neurologist Robert P. Friedland.

Creutzfeldt Jakob disease is commonly known as mad cow disease. Creutzfeldt Jakob is a disease for which there is no treatment and it is fatal. The diseases can be contracted by eating parts of an animal infected with bovine spongiform encephalopathy (BSE or mad cow disease).

You might recall that an outbreak of "mad cow" in England set off quite a reaction several years ago. There was a good result as many countries outlawed feeding rendered cow material to other cattle because the disease is so easily spread within the same species. There are only three known cases of mad cow in the U.S.

Here is one key quote from Dr. Friedland,
We have not proven that it’s possible for fish to transmit the disease to humans. Still, we believe that out of reasonable caution for public health, the practice of feeding rendered cows to fish should be prohibited...Fish do very well in the seas without eating cows.
A bigger issue might be the nutritional value of farmed fish and whether humans are getting what they are really after-- long-chain omega-3 fatty acids.

These articles reminded me of the article I wrote about Boston Legal and Denny Crane (played by William Shatner). Denny who suffered from mad cow (Alzheimer's), went to the Supreme Court to get approval to take the drug Dimebon. The show ended its run on television with Denny winning his Supreme Court case, and winning the right to take Dimebon.

Americans are patiently waiting for the results of the ongoing clinical trials of Dimebon. Dimebon is a twenty five year old drug that is not currently available to U.S. citizens.

Dimebon is an orally-available, small molecule that has been shown to inhibit brain cell death in preclinical models relevant to Alzheimer’s. Medivation is currently conducting several phase three clincial trials with Dimebon.

See Dimebon Connection Study Complete, Additional Phase 3 Trials Still Open
Subscribe to The Alzheimer's Reading Room

Bob DeMarco is an Alzheimer's caregiver and editor of the Alzheimer's Reading Room. The Alzheimer's Reading Room is the number one website on the Internet for advice and insight into Alzheimer's disease. Bob taught at the University of Georgia, was an executive at Bear Stearns, the CEO of IP Group, and is a mentor. He has written more than 700 articles with more than 18,000 links on the Internet. Bob resides in Delray Beach, FL.

More from the Alzheimer's Reading Room

Post a comment
Write a comment:

Related Searches